The Effects of GABA Agonism on MPD Sensitization by Newman, Tyler
Digital Kenyon: Research, Scholarship, and Creative Exchange
Kenyon Summer Science Scholars Program Summer Student Research Scholarship
Summer 2004
The Effects of GABA Agonism on MPD
Sensitization
Tyler Newman
Follow this and additional works at: https://digital.kenyon.edu/summerscienceprogram
Part of the Psychology Commons
This Poster is brought to you for free and open access by the Summer Student Research Scholarship at Digital Kenyon: Research, Scholarship, and
Creative Exchange. It has been accepted for inclusion in Kenyon Summer Science Scholars Program by an authorized administrator of Digital Kenyon:
Research, Scholarship, and Creative Exchange. For more information, please contact noltj@kenyon.edu.
Recommended Citation
Newman, Tyler, "The Effects of GABA Agonism on MPD Sensitization" (2004). Kenyon Summer Science Scholars Program. Paper 293.
https://digital.kenyon.edu/summerscienceprogram/293
The Effects of GABA Agonism on MPD Sensitization
Tyler Newman and Hewlet McFarlane, PhD.
Kenyon College Summer Science Program
  
-1000
0
1000
2000
3000
4000
5000
6000
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 26
Day
T
o
t
a
l 
D
is
t
a
n
c
e
 M
o
v
e
d
 
(
c
m
)
Saline Average: Val Average MPD Average: MPD+Val Average
0
100
200
300
400
500
600
Days 1-5 Days 6-10 Days 11-15 Days 16-20 Day 26
Day(s)
A
v
e
r
a
g
e
 N
u
m
b
e
r
 o
f
 S
t
e
r
e
o
t
y
p
ic
 M
o
v
e
m
e
n
t
s
 
M
a
d
e
Saline Average: MPD Average: Val Average MPD+Val Average
   
-10
0
10
20
30
40
50
60
70
80
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 26
Day
N
u
m
b
e
r
 o
f 
V
e
r
ti
c
a
l 
M
o
v
e
m
e
n
ts
Saline Average Val Average MPD Average MPD+Val Average:
Introduction
Sensitization is the process by which an organism will show a greater reaction to 
a drug because of prior experiences with the same or a similar drugs. Recent animal 
studies have shown that methylphenidate given to animals, sensitizes them to 
amphetamines, a potentially dangerous drug class (Yang, Swann & Dafny, 2003). 
Methylphenidate is similar to amphetamines and cocaine in that it functions by 
increasing the dopamine available in mammalian brains (Grace, 1994). The dopamine 
system is part of the reward system which has positive reinforcing effects on behaviors 
in animals.
In response to the evidence that MPD amphetamine sensitization, there is 
evidence that GABAergic drugs are able to counter the effect (Yang, Beasley, Swann & 
Dafny, 2000). Yang et al., 2000, asserts that this effect is largely due to the indirect and 
direct action of GABA agonists on dopamine neurons (Cooper, Bloom & Roth, 1996). 
Sodium valproate, a GABA agonist, does not affect the motor activity induced by 
methylphenidate, but blocks the sensitization effect of the drug (Eckerman, Beasley, 
Yang, Gaytan, Swann & Dafny, 2000). Given prior to chronic treatment of MPD, 
valproate effectively blocked the locomotor sensitization to later acute administration 
of MPD. The effect of valproate on MPD cross-sensitization to amphetamine was not 
examined, however it is cited as an area for future research (Yang et al., 2000). For 
these reasons it is hypothesized that MPD will cross-sensitize animals to amphetamine 
and that GABA agonism with Valproate will abolish this effect.
Subjects
Thirty-two juvenile (21-47 days old), male Sprague-Dawley rats were used for 
this experiment. At birth the animals were housed in groups of eight with litter mates, 
at 20 days old the rats were separated into pairs and housed in pairs for the remainder 
of the experiment. Animals are housed in pairs to avoid isolation effects on locomotion 
behaviors.
Apparatus
The animals were tested in an open-field activity and will be measured in a 
Versamax Animal Activity Monitoring System (AccuScan Intruments, Inc., Columbus, 
OH).  This system is made of a clear Plexiglas cage with the dimensions 42 x 42 x 30 
cm with two sets of 16 x 16 photo-beams arranged to measure both horizontal and 
vertical movements of the subjects, spaced 2.5 cm apart. Beams measuring vertical 
movements are placed 10 cm above the floor of the cage, while the beams measuring 
the horizontal movements of the subjects are placed at the base of the cage. The 
information from the activity monitors is fed to the Versamax analyzer, which is 
connected to a computer (Compact, Pentium III, Windows, 2000).
Discussion
It was expected that chronic MPD treatment would lead to behavioral 
sensitization to an acute dose of amphetamine and that combining valproate with MPD 
would abolish this effect. Although AMPH sensitization was not observed, the current 
study clearly demonstrated that MPD is a behavioral stimulant to which the animals did 
not adapt during the course of the study. The total distance chart (Fig. 1) clearly shows 
that MPD is a stimulant to which rats respond to with increased locomotion. However, 
the subjects never adapted to this treatment and do not appear to react differently to the 
amphetamine treatment, as was hypothesized. This may explain why sensitization was 
not observed; perhaps MPD treatment resulted in maximal behavior so that there was a 
ceiling effect above which no increase in behavior could be observed. This hypothesis 
will be tested using a lower dose of MPD. It is also possible that the lack of a 
behavioral effect in response to acute amphetamine treatment is due to the development 
of cross-tolerance to the amphetamine as a result of the chronic doses of MPD. Our 
follow-up studies will also answer this question.
However, what was most interesting in this study was the effect of combining 
MPD treatment with Valproate. Valproate appears to abolish the stimulant effects of 
MPD so that the animals in this group behave similarly to controls suggesting that 
Valproate “normalized” the animals’ behavior. In keeping with the literature (Yang et 
al., 2002), it should be noted that Valproate by itself in the dose given, did not appear 
to have significant effects on the animals’ behavior, although a non-significant decline 
was observed (Yang et al., 2002). Given these results, the question that remains to be 
answered is whether the behavioral “normalizing” effect of valproate is due to pre-
synaptic mechanisms which results in diminished dopamine release, post-synaptic 
mechanisms which mediates the effects of the MPD-induced increase in synaptic 
dopamine, or both. This question will also be addressed in a follow-up study.  
Given the widespread use of MPD (Ritalin) in society, it is important to 
understand its mechanism of action as well as its addictive and abuse potential. Our 
study suggests that MPD’s stimulant effects may blunt or diminish the effects of later 
amphetamine use. If this holds true for human populations, then it suggests people who 
try amphetamines after a chronic exposure to MPD will need bigger doses to achieve 
an effect (get “high”). This could lead to persons in that population using bigger doses, 
which could lead to a greater likelihood of the occurrence of toxic effects. Further, our 
data suggests that combining the chronic MPD treatment with valproate may allow 
those individuals to have a normal response to later amphetamine use. Clearly this 
needs further study. 
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Figure 5 Figure 6
Stereotypic Movements Made
Figure 3 Figure 4
Vertical Movements Made
Figure 1 Figure 2
Total Distance Moved
A one-way repeated measures analysis of variance was used to analyze the statistical differences of total 
distance moved between drug groups. The obtained F ratio analyzing total distance moved was found to be 
statistically significant, F (4.5, 42.1) = 14.88, p < .001. A Student-Newman-Keuls post hoc test showed no 
differences between the Saline, Valproate or the MPD + Valproate groups. However, the MPD group was 
significantly more active than the other groups at an alpha level of .05.
Results
A one-way repeated measures analysis of variance was used to analyze the statistical differences of vertical 
movements made between drug groups. The obtained F ratio analyzing vertical movements made was found to 
be statistically significant, F (5.1, 47.3) = 16.41, p < .001. A Student-Newman-Keuls post hoc test with an alpha 
level of .05 showed no significant difference between the MPD + Valproate group, Valproate group or the Saline 
group. There was a significant difference between the MPD group and the MPD + Valproate group as well as the 
Valproate group, yet there was no significant difference between the MPD group and the Saline group. 
A one-way repeated measures analysis of variance was used to analyze the statistical differences of 
stereotypic movements made between drug groups. The obtained F ratio analyzing the number of 
stereotypic movements made was found to be statistically significant, F (5.4, 50.4) = 22.00, p < .001. A 
Student-Newman-Keuls post hoc test with an alpha level of .05 showed that there was not significant 
difference between the Saline group and the MPD + Valproate group. These two groups did show 
significantly more activity than the Valproate group and significantly less than the MPD group.
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Abstract
The purpose of this study was to assess whether chronic Methylphenidate (MPD) 
treatment leads to later amphetamine sensitization, and whether Valproate, a GABA 2a 
agonist would block this effect. 32 animals were divided into 4 test groups: Saline, 
MPD (2.5 mg/kg), Valproate (50 mg/kg) and MPD and Valproate (2.5 mg/kg and 50 
mg/kg respectively). The behavioral effects of these drug treatments were tested one 
hour on a daily basis for 20 days in Versamax activity monitors on three locomotor 
behaviors: total distance traveled, number of vertical movements made, and number of 
stereotypic movements made. After 20 days of chronic treatment, the subjects were 
given a five-day wash out (no drug treatment) period and on the 26th day given a 
challenge dose of amphetamine. The results indicate that on all measures, MPD acted 
as a behavioral stimulant throughout and that MPD treated animals were not sensitized 
to amphetamine. However, Valproate abolished the stimulant effects of MPD, and all 
groups except the MPD group had a robust response to acute AMPH treatment.
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